Overall study population was KRAS-
unselected (n=154)
†
n=85;
‡
n=68
PANITUMUMAB + Quimioterapia:
FOLFIRI + Panitumumab
•
1. Köhne CH, et al. J Cancer Res Clin Oncol 2012;138:65–72;
2. Karthaus M, et al. ESMO 2014 (Abstract No. 549P)
Endpoint
KRAS exon 2 wt
1
(n=86)
RAS wt
2
(n=69)
ORR, %
56
†
59
‡
CR, %
2
†
3
‡
PR, %
54
†
56
‡
SD, %
34
†
32
‡
Patients with R0 resection,
%
8
6
Median DoR, months
13.0
13.0
Median PFS, months
8.9
11.2
Median TTP, months
11.2
13.2
Median TTF, months
6.9
NR
